• Vincent L Butty, Pascale Roux-Lombard, Jorge Garbino, Jean-Michel Dayer, Bara Ricou, and Geneva Sepsis Network.
• Department of Anesthesiology, Pharmacology and Surgical Intensive Care, Geneva University Hospital, 1211 Geneva 14, Switzerland.
• Eur. Cytokine Netw. 2003 Jan 1;14(1):15-9.

ObjectivesTo investigate the effects of Lenercept , a recombinant soluble TNF receptor p55 fused to an immunoglobulin heavy chain IgG1, on the balance of pro- and anti-inflammatory mediators in sepsis.DesignPost hoc analysis of a subgroup of patients enrolled in a multicenter phase III, prospective, double-blind, placebo-controlled, randomized study of Lenercept in severe sepsis.SettingSurgical and medical intensive care units, and postoperative recovery room of a tertiary care teaching hospital.PatientsA total of 57 patients were enrolled in the multicenter study in our center.InterventionSeptic patients were randomly assigned to receive either Lenercept 0.125 mg/kg or placebo. The patients were followed for up to 28 days after randomization.Measurements And Main ResultsCirculating levels of TNF-alpha, IL-6, TNFsR75 and IL-1Ra were measured before and after treatment. The two groups were comparable with regard to age, gender and diagnosis distribution. The total level of TNF-alpha increased significantly in treated patients, compared to patients receiving placebo. The levels of the other inflammatory mediators did not differ between the two groupsConclusionsLenercept -treated patients experienced a protracted TNF-alpha half-life, leading to higher total TNF-alpha levels throughout the study. However, the treatment had no effects on anti-inflammatory mediators. Therefore, peripheral inflammatory processes might not have been significantly modified by the treatment. This might account for the lack of efficacy this treatment in septic patients

29 keywords...

hide…